Author of

• 32099

  +

  EP1.12 - Small Cell Lung Cancer/NET (ID 202)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Small Cell Lung Cancer/NET
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32137

    +

    EP1.12-35 - Comparison of Long Term Results Between Matched Chemoradiotherapy and Surgery for Limited Stage Small Cell Lung Cancer (ID 247)

    08:00 - 18:00  |  Author(s): Xiao Hu
    • Abstract
    • Slides

    Background
    

    The role of surgery in patients with SCLC is undefined. Our study was conducted to compare the long term results of chemoradiotherapy with surgical treatment for limited stage SCLC.To compare the efficacy of chemoradiotherapy or surgery for limited-stage small cell lung cancer (SCLC).

    Method
    

    A retrospective analysis was performed on 138 patients with limited-stage SCLC who received surgery (69 patients) or chemoradiotherapy (69 patients) between January 2000 and September 2016 in Zhejiang Cancer Hospital. Patients of the chemoradiotherapy group were selected by using ‘pair-matched case-control’ methodology from a cohort of 503 patients who received chemoradiotherapy.

    Result
    

    The major prognostic factors including T, N stage, treatment duration, age, gender, and whether or not received prophylactic cranial irradiation were well balanced between two groups. The median overall survival (OS) time and 5-year OS rate were 37.1 months and 45.0% in surgical group versus 45.0 months and 45.0% in chemoradiotherapy group (P=0.846). The median progression-free survival (PFS) time and 5-year PFS rate were 27.1 months and 37.8% versus 36.2 months and 40.0% respectively in the two groups (P=0.610). The 5-year OS rate (62.3% vs. 40.1%, P=0.038) and 5-year PFS rate (80.1% vs. 40.1%, P=0.048) in surgical group were significantly higher than those of chemoradiotherapy group in patients with stage I disease. While the 5-year OS rate (41.2% vs. 50.6%, P=0.946), 5-year PFS rate (64.7% vs. 42.1%, P=0.280) of surgery for stage II SCLC were comparable to chemoradiotherapy. As for stage III SCLC, compared with the surgical group, the chemoradiotherapy group had a better 5-year OS trend (25.1% vs. 47.6%, P=0.220).

    Conclusion
    

    Surgery could confer survival benefit in patients with p-stage I disease, but not in patients with p-stage II and III disease.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.